about
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic KinasesTyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsApplications of chemogenomic library screening in drug discoveryActivation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.Discovering and understanding oncogenic gene fusions through data intensive computational approaches2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes.KAOS: a new automated computational method for the identification of overexpressed genes.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Chemical Methods for Encoding and Decoding of Posttranslational ModificationsDesign, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1)Antagonizing STAT5B dimerization with an osmium complex.Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents.Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.Progress towards a public chemogenomic set for protein kinases and a call for contributions.A SMAP in the face for cancer.On the pharmacogenetics of non-small cell lung cancer treatment.Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivoRANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I studyGlycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelAn Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.Functional phosphatome requirement for protein homeostasis, networked mitochondria, and sarcomere structure in C. elegans muscle.Reproducible Bioconductor workflows using browser-based interactive notebooks and containers.Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.Ubiquitin ligases in oncogenic transformation and cancer therapy.Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs.Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs.Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.Estimation of pH effect on the structure and stability of kinase domain of human integrin-linked kinase.
P2860
Q27313731-7B836A36-0970-4E66-8417-50801702ACAFQ28078946-F62564F2-8D55-46DA-ACBA-FE5F3D7E4D67Q28656335-10620651-F53A-4835-AAED-3188CCD15CE8Q30252408-E00CF68E-84F0-4E7B-AB00-FE273D0FE387Q31083417-C0A95246-9E2A-4ED2-8158-CAC14FD5A9EFQ33698756-1879389E-845A-494E-AD06-B07EC764BC8DQ33792598-71E6346D-EF97-4034-A2EE-C9748E7898A3Q35947378-FFB01E5D-1BCD-4F7E-BEA2-383C98EAD2A8Q36276385-8AE4D971-5CA3-4BB3-ABB7-D0994AFDAAE4Q36600202-8AD436DA-BA28-43E4-8A8C-A3543ACD4710Q36654176-46E3A0E8-F69A-45BC-8FEF-8B23EA2356D5Q36748138-AA26B775-A203-40DA-BF54-E37DA7AFF4FFQ37419916-087BEB53-BE97-46CC-BF01-EDF15198F2DBQ37627010-1DFB0C72-4F8E-49BC-BDAB-D950A5908BC3Q37737964-7FFB26B5-2349-429D-BBEA-67C714A54DC8Q38616707-80B4E002-FED0-4617-B5EA-BC5A3DFD3F94Q38646648-DC014EAC-376F-4039-9D48-C70CAC857ECFQ38683842-87A115F3-51AD-41F3-869E-CED2189A841CQ38694947-4B33AFFD-5035-4C4A-A54A-4F411DC92CD3Q38707201-1CDE2375-3CD5-43CF-983F-1FAC0EE721C3Q38804090-5FD010DC-F8E1-4A79-80E0-F42BEAD3B4B9Q38888255-8E03135F-8AC1-41E4-BA44-AE03120D9BDEQ38969858-C59DA90E-B1AA-4AAE-8D3F-90AA03AEE68DQ38979882-393FC819-9F2E-41C1-8A67-66A8D0849EFBQ39003757-2B994604-E1FD-46D2-AE70-66D0DC44A419Q39120175-D238A940-9352-4FBB-9646-E8510EAF95C3Q39249589-C9B668FD-682F-4145-B054-AA07C1468EE8Q39394159-B6C848F6-C704-4692-AB28-20C495019DDEQ40065688-4A47A133-F476-4D1C-BC59-8568FB091061Q41485482-7B337C2D-3903-417E-8518-F358F9A89423Q42695276-2CD2DD6E-8D72-410A-B63E-B18D9D61BF32Q46254792-D98CD933-43CF-4E95-AAF9-30D561B7A13FQ46488626-CDBF5505-DD95-46A2-AB56-5F9BB8976F52Q46609299-E801E0E8-4E16-461D-9082-56005FE6D398Q46916610-096F5A25-BA20-4196-95F8-7A827D499AFDQ47123651-AB08A564-2D92-4A2A-8FD2-64FB0C834E33Q47221234-6EF6D2DD-FE61-41EF-9C20-D82F9DBE96F1Q47235181-AC13CFCA-3385-4E7D-B182-A90B3EBF90C9Q47252106-A3377703-9F7F-4EAB-AA19-2178CB6D08D6Q47264014-520A3627-5F66-4300-AD10-46278132399E
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeting cancer with kinase inhibitors
@ast
Targeting cancer with kinase inhibitors
@en
Targeting cancer with kinase inhibitors
@nl
type
label
Targeting cancer with kinase inhibitors
@ast
Targeting cancer with kinase inhibitors
@en
Targeting cancer with kinase inhibitors
@nl
prefLabel
Targeting cancer with kinase inhibitors
@ast
Targeting cancer with kinase inhibitors
@en
Targeting cancer with kinase inhibitors
@nl
P2093
P2860
P3181
P356
P1476
Targeting cancer with kinase inhibitors
@en
P2093
Klaus P. Hoeflich
Rami Rahal
Stefan Gross
P2860
P304
P3181
P356
10.1172/JCI76094
P407
P577
2015-05-01T00:00:00Z